WEBULL

Why Investors Shouldn't Be Surprised By GeneDx Holdings Corp.'s (NASDAQ:WGS) 28% Share Price Surge

Simply Wall St · 06/27 10:23

Those holding GeneDx Holdings Corp. (NASDAQ:WGS) shares would be relieved that the share price has rebounded 28% in the last thirty days, but it needs to keep going to repair the recent damage it has caused to investor portfolios. The annual gain comes to 243% following the latest surge, making investors sit up and take notice.

Since its price has surged higher, you could be forgiven for thinking GeneDx Holdings is a stock to steer clear of with a price-to-sales ratios (or "P/S") of 7.7x, considering almost half the companies in the United States' Healthcare industry have P/S ratios below 1x. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

View our latest analysis for GeneDx Holdings

ps-multiple-vs-industry
NasdaqGS:WGS Price to Sales Ratio vs Industry June 27th 2025

How GeneDx Holdings Has Been Performing

GeneDx Holdings certainly has been doing a good job lately as it's been growing revenue more than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

Keen to find out how analysts think GeneDx Holdings' future stacks up against the industry? In that case, our free report is a great place to start.

Do Revenue Forecasts Match The High P/S Ratio?

GeneDx Holdings' P/S ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the industry.

Retrospectively, the last year delivered an exceptional 49% gain to the company's top line. Pleasingly, revenue has also lifted 63% in aggregate from three years ago, thanks to the last 12 months of growth. Therefore, it's fair to say the revenue growth recently has been superb for the company.

Looking ahead now, revenue is anticipated to climb by 17% per year during the coming three years according to the six analysts following the company. With the industry only predicted to deliver 7.4% per annum, the company is positioned for a stronger revenue result.

With this in mind, it's not hard to understand why GeneDx Holdings' P/S is high relative to its industry peers. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

What Does GeneDx Holdings' P/S Mean For Investors?

Shares in GeneDx Holdings have seen a strong upwards swing lately, which has really helped boost its P/S figure. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

As we suspected, our examination of GeneDx Holdings' analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. Right now shareholders are comfortable with the P/S as they are quite confident future revenues aren't under threat. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.

It is also worth noting that we have found 1 warning sign for GeneDx Holdings that you need to take into consideration.

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.